Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Yoseph Shaaltiel"'
Autor:
Maor Sheva, Uri Hanania, Tami Ariel, Albina Turbovski, Vishal Kumar Rameshchandra Rathod, Dina Oz, Yoram Tekoah, Yoseph Shaaltiel
Publikováno v:
Frontiers in Plant Science, Vol 11 (2020)
While plant cells in suspension are becoming a popular platform for expressing biotherapeutic proteins, the need to pre-engineer these cells to better comply with their role as host cell lines is emerging. Heterologous DNA and selectable markers are
Externí odkaz:
https://doaj.org/article/658f67c60f784860bcf490b63026a503
Autor:
Yaron Ilan, Yoseph Shaaltiel, Raul Chertkoff, Alona Paz, Mattitiahu Waterman, Hadar Reuveni, Mali Szlaifer, Sari Alon, Alexander Fich, Doron Schwartz, Bat-chen Amit-Cohen, Einat Almon, Wisam Sbeit
Publikováno v:
Journal of Clinical Gastroenterology. 55:134-140
BACKGROUND AND OBJECTIVE OPRX-106 is an orally administered BY2 plant cell-expressing recombinant TNF fusion protein (TNFR). Oral administration of OPRX-106 was shown to be safe and effective in inducing favorable anti-inflammatory immune modulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13253e5f7e945ede09832013e3592746
https://doi.org/10.1097/mcg.0000000000001314
https://doi.org/10.1097/mcg.0000000000001314
Autor:
Dina Oz, Tami Ariel, Yoseph Shaaltiel, Uri Hanania, Albina Turbovski, Yoram Tekoah, Vishal Kumar Rameshchandra Rathod, Maor Sheva
Publikováno v:
Frontiers in Plant Science
Frontiers in Plant Science, Vol 11 (2020)
Frontiers in Plant Science, Vol 11 (2020)
While plant cells in suspension are becoming a popular platform for expressing biotherapeutic proteins, the need to pre-engineer these cells to better comply with their role as host cell lines is emerging. Heterologous DNA and selectable markers are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a02ca56c550abe18bed9d292972f4e
https://doi.org/10.3389/fpls.2020.607174
https://doi.org/10.3389/fpls.2020.607174
Autor:
David Aviezer, Einat Brill-Almon, Yoseph Shaaltiel, Sharon Hashmueli, Daniel Bartfeld, Sarah Mizrachi, Yael Liberman, Arnold Freeman, Ari Zimran, Eithan Galun
Publikováno v:
PLoS ONE, Vol 4, Iss 3, p e4792 (2009)
Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase leading to the dysfunction in multiple organ systems. Intravenous enzyme replacement is the accepted standard of treatment. In the current repo
Externí odkaz:
https://doaj.org/article/b2527cbc468541b990a3b4f680f4d372
Autor:
Yoseph Shaaltiel, Yehuda Gubbay, Yoram Tekoah, Mara Weiss, Albina Turbovski, Dina Oz, Liat Fux, Maor Sheva, Yehava Forster, Tami Ariel, Yaniv Azulay, Uri Hanania
Publikováno v:
Plant Biotechnology Journal
Summary Plant‐produced glycoproteins contain N‐linked glycans with plant‐specific residues of β(1,2)‐xylose and core α(1,3)‐fucose, which do not exist in mammalian‐derived proteins. Although our experience with two enzymes that are used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08172e80ef2fe41470cb46e101a45b04
https://doi.org/10.1111/pbi.12702
https://doi.org/10.1111/pbi.12702
Autor:
Yakir Nataf, Avidor Shulman, Yoram Tekoah, Yaniv Azulay, Yoseph Shaaltiel, Ilya Ruderfer, Tali Kizhner
Publikováno v:
Bioconjugate chemistry. 29(5)
The current treatment of Fabry disease by enzyme replacement therapy with commercially available recombinant human α-Galactosidase A shows a continuous deterioration of the disease patients. Human recombinant α-Galactosidase A is a homodimer with n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace6d859d5159c6fe62831939dfb6ac7
https://pubmed.ncbi.nlm.nih.gov/29698600
https://pubmed.ncbi.nlm.nih.gov/29698600
Autor:
Hermona Soreq, Avidor Shulman, Tehila Ben-Moshe, Kirsten Y. Haim, Jacob Atsmon, Sari Alon, Carmit Nadri-Shay, Einat Brill-Almon, Orit Shilovitzky, Raul Chertkoff, Ilya Ruderfer, Inna Volokhov, Dimitri Shaikevich, Daniel Bartfeld, Yoseph Shaaltiel
Publikováno v:
Toxicology and Applied Pharmacology. 287:202-209
PRX-105 is a plant-derived recombinant version of the human ‘read-through’ acetylcholinesterase splice variant (AChE-R). Its active site structure is similar to that of the synaptic variant, and it displays the same affinity towards organophospho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee0ba669a170cebb006d2aac387a39a
https://doi.org/10.1016/j.taap.2015.06.004
https://doi.org/10.1016/j.taap.2015.06.004
Autor:
Yoram Tekoah, Avidor Shulman, Yakir Nataf, Yoseph Shaaltiel, Svetlana Gingis-Velitski, Daniel Bartfeld, Uri Hanania, Liat Fux, Tami Ariel, Ilya Ruderfer, Tali Kizhner
Publikováno v:
Plant Biotechnology Journal. 13:1199-1208
Summary Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Oth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65edbccca2032804dae32e824607446d
https://doi.org/10.1111/pbi.12428
https://doi.org/10.1111/pbi.12428
Autor:
Nadia Fiks, Yoseph Shaaltiel, Yoram Tekoah, Salit Tzaban, Svetlana Gingis-Velitski, David Aviezer
Publikováno v:
Plant Biotechnology Journal. 13:1033-1040
Summary Gaucher's disease (GD), a lysosomal storage disorder caused by mutations in the gene encoding glucocerebrosidase (GCD), is currently treated by enzyme replacement therapy (ERT) using recombinant GCD that is administered intravenously every 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ea353b8406e8e9de28ae5b3a573c2f
https://doi.org/10.1111/pbi.12366
https://doi.org/10.1111/pbi.12366
Autor:
Avidor Shulman, Tali Kizhner, Yaniv Azulay, David Aviezer, Gil Arvatz, Mariana Hainrichson, Ilya Ruderfer, Yoram Tekoah, Yoseph Shaaltiel
Publikováno v:
Molecular Genetics and Metabolism. 114:259-267
Fabry disease is an X-linked recessive disorder caused by the loss of function of the lysosomal enzyme α-Galactosidase-A. Although two enzyme replacement therapies (ERTs) are commercially available, they may not effectively reverse some of the Fabry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::518b8ad0c9f88b3d17aeabcc65d3cfd0
https://doi.org/10.1016/j.ymgme.2014.08.002
https://doi.org/10.1016/j.ymgme.2014.08.002